[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colon-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colon-neoplasms":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100633611","application-of-3d-reconstruction-for-preoperative-strategy-of-locally-advanced-colon-cancer-100633611",false,"NCT07528937","Application of 3D Reconstruction for Preoperative Strategy of Locally Advanced Colon Cancer","Randomized Multicenter Study Protocol: Application of 3D Reconstruction for Preoperative Strategy of Locally Advanced Colon Cancer","Inclusion Criteria:\n\n1. Patients of both sexes, aged ≥18 years.\n2. Adenocarcinoma of the right, left, sigmoid and recto-sigmoid junction that have cT3 or cT4a\u002Fb according to the eighth TNM edition of the American Joint Committee on Cancer (AJCC). Pre-treatment diagnosis by imaging (CT) test.\n3. Lymph node extension: cN0, the presence of cN1\u002F2 according to AJCC TNM 8th edition is allowed as long as they can be resected. Pretreatment diagnosis by imaging (CT) test.\n4. Patients who access and sign informed consent for the surgical intervention.\n\nExclusion Criteria:\n\n1. Suspected carcinomatosis on preoperative CT or intraoperative finding\n2. Suspected distant metastasis on preoperative CT or intraoperative finding\n3. Patients with tumors with infiltration considered to be unresectable (pre-surgical or intraoperatively), since the anatomical-pathological analysis will not be available.","ALL","18 Years",{"count":19,"type":20},168,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim of this study is to assess the usefulness of a mathematical model of three-dimensional image process and reconstuction (3D-IPR) as a surgical planner in locally advanced colon cancer. In addition to comparing the diagnostic accuracy of this planner with that of the CT regarding the infiltration of neighbouring structures.",[26,27,28],"Colon Neoplasms","Locally Advanced Colon Cancer","3D Reconstruction",[30,31,28],"Locally advanced colon cancer","Colon neoplasm","NOT_YET_RECRUITING","2026-04-16",{"date":35,"type":36},"2026-04-21","ACTUAL",{"date":38,"type":20},"2026-05-01",{"date":40,"type":20},"2031-05-01",{"name":42,"class":43},"Fundació d'investigació Sanitària de les Illes Balears","OTHER_GOV",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100604796","comprehensive-analysis-of-gut-microbiota-signatures-in-metastatic-colorectal-cancer-100604796","NCT07154173","Comprehensive Analysis of Gut Microbiota Signatures in Metastatic Colorectal Cancer","Inclusion Criteria:\n\n* Age between 18 and 75 years\n* Pathologically confirmed colorectal cancer\n* Clearly defined clinical staging: including imaging or pathologically confirmed metastatic colorectal cancer (stage M1) and colorectal cancer without distant metastasis (stage M0)\n* Expected survival ≥ 3 months\n* Voluntary participation and signed informed consent\n\nExclusion Criteria:\n\n* Use of probiotics, antibiotics, or immunosuppressive agents within 1 month before surgery\n* Preoperative complete intestinal obstruction or gastrointestinal perforation\n* Intraoperative gastrointestinal perforation or tumor rupture\n* Previous history of gastrointestinal surgery (excluding colorectal cancer surgery, appendectomy, and cholecystectomy) or concurrent severe gastrointestinal diseases such as inflammatory bowel disease\n* Concurrent active systemic immune or infectious diseases, including severe allergies, rheumatoid arthritis, systemic lupus erythematosus, viral hepatitis, acquired immunodeficiency syndrome, etc.\n* Concurrent unhealed primary malignant tumors\n* Severe organ dysfunction or failure\n* Other conditions deemed unsuitable for this study by the investigator",true,"75 Years",{"count":53,"type":20},300,"1 Year","OBSERVATIONAL","Colorectal cancer (CRC) is one of the most common and deadly cancers worldwide. About 1 in 4 people with CRC already have cancer spread (metastasis) when first diagnosed, and about half develop spread during their illness. Recent research shows that bacteria living in the gut and even within tumors might play an important role in how cancer spreads.\n\nThe goal of this study is to better understand how bacteria might influence the spread of colorectal cancer. The main questions the investigators aim to answer are:\n\nAre there differences in bacteria between people whose cancer has spread and those whose cancer has not spread? Could certain bacteria help predict which cancers might spread?\n\nTo answer these questions, the investigators will:\n\nCollect different types of samples from participants:\n\nTumor tissue Normal tissue near the tumor Tissue from where cancer has spread Stool samples before surgery Study the bacteria in these samples using advanced testing methods Compare bacterial patterns between different groups\n\nPeople can take part in this study if they:\n\nAre between 18 and 75 years old Have colorectal cancer confirmed by doctors Have not taken antibiotics recently Do not have immune system problems\n\nThis research may help us:\n\nUnderstand why some colorectal cancers spread Find new ways to predict which cancers might spread Develop better treatments for colorectal cancer",[58,26,59,60],"Rectal Neoplasms","Microbiota","Metagenome",[62,63,64,65],"rectal neoplasms","colon neoplasms","microbiota","metagenomics","RECRUITING","2025-12-26",{"date":69,"type":36},"2025-12-31",{"date":71,"type":36},"2025-01-01",{"date":73,"type":20},"2026-12-31",{"name":75,"class":76},"Sixth Affiliated Hospital, Sun Yat-sen University","OTHER",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":89,"conditions":90,"keywords":102,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":77},"100566245","sentinel-node-and-organ-sparing-surgery-in-stage-i-colon-carcinoma-100566245","NCT06652672","Sentinel Node and Organ-sparing Surgery in Stage I Colon Carcinoma","Sentinel Node and Organ-sparing Surgery in Stage I Colon Carcinoma (SENTRY Trial)","SENTRY","Inclusion Criteria:\n\n* Oral and written informed consent (IC)\n* Aged 18 years and older\n* Fit for both organ-sparing surgery and colectomy\n* Pathologically confirmed T1-2 adenocarcinoma of the colon following R0, R1, or Rx endoscopic resection with an estimated LNM risk \\>15% (Table 5.2.2. in module 5.2 of the Dutch CRC guideline); or a lesion macroscopically suspected to be (deep-invasive) T1 colon cancer, measuring \\\u003C40 mm, for which wedge resection is considered the most suitable local resection technique as recommended by the MDT\n* The resection scar after local excision is expected to be clearly recognized at endoscopy, either by a tattoo or by detecting a scar in the colorectal segment where no other polypectomies were performed\n* Lesion located \\>25cm from the anus based on endoscopic measurement, or above sigmoid take-off\n\nExclusion Criteria:\n\n* Patients who opt for active follow-up instead of surgery following shared decision-making\n* Distant metastasis\n* Lynch syndrome\n* Another active malignancy requiring palliative treatment at the time of colon cancer diagnosis\n* Previous colorectal cancer within the last 5 years\n* Tumours that comprised \\>50% of the colon circumference before resection\n* Tumours involving the ileocaecal valve\n* Pregnancy, lactation or a planned pregnancy during the course of the study\n* Known allergy to any of the compounds used for SLN identification (ICG, Iodine or Sodium iodide)\n* Previous colonic surgery (excluding appendectomy)\n* Contra-indication for laparoscopic or robotic surgery\n* Severe kidney- or liver failure\n* Hyperthyroidism or an autonomously functioning thyroid adenoma",{"count":87,"type":20},341,[23],"The aim of this study is to reduce the need for colectomy and its' associated morbidity and mortality in patients with pT1-2 colon carcinoma after endoscopic resection and an estimated lymph node metastasis (LNM) risk of \\>15%, or with macroscopically suspected T1 tumors, by performing an endoscopic-assisted laparoscopic\u002Frobotic wedge resection of the tumor or scar, along with sentinel node (SLN) biopsy using indocyanine green (ICG). This intervention will be compared to the standard-of-care segmental resection using a partially randomized patient preference design. The primary outcome is the 3-year recurrence rate.",[91,92,93,94,26,95,96,97,98,99,100,101],"Colon Cancer","Colon Adenocarcinoma","Sentinel Lymph Node","Sentinel Lymph Node Biopsy","Colon Neoplasm","Fluorescence","Fluorescence Guided Surgery","Fluorescence Laparoscopy","Fluorescence-guided Resection","Colon Surgery","Indocyanine Green (ICG)",[103,96,104,105,106,107,108],"Colon cancer","Sentinel lymph node","Indocyanine green (ICG)","Organ sparing surgery","Organ preserving surgery","Local resection","2025-11-17",{"date":111,"type":36},"2025-11-20",{"date":113,"type":36},"2024-12-12",{"date":115,"type":20},"2032-12-12",{"name":117,"class":76},"Meander Medical Center"]